November 15, 2021
Bayer AG said on November 10 that it has filed its VEGF inhibitor Eylea (aflibercept) for an additional indication for the treatment of premature babies with retinopathy of prematurity (ROP) in Japan and Europe. The submissions made in both markets...read more